A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

NCT05931367 · Completed

Last updated 2026-05-28

This clinical trial is testing whether a weekly injection of retatrutide helps reduce knee pain in adults who have obesity or overweight and osteoarthritis of the knee.

Status Completed The study has finished.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, double-blind treatment study

Participants 445 people

Who can join Ages 18+ · all sexes

Timeline Started 2023-08 · est. completion 2025-11

Where 49 sites · Australia, Canada, Mexico, Spain, United Kingdom, United States

What this study is testing ClinicalTrials.gov NCT05931367 ↗

Description as written by the study sponsor.

The main purpose of this study is to evaluate the safety and efficacy of retatrutide once-weekly in participants who have obesity or are overweight and have osteoarthritis (OA) of the knee. The study will lasts about 77 weeks.

Treatments tested

Retatrutide also known as LY3437943 Drug

Administered SC
Placebo Drug

Administered SC

Main thing measured	Change from Baseline in the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain Subscale Score
Sponsor	Eli Lilly and Company
Conditions studied	Obesity, Overweight, Osteo Arthritis Knee
GLP-1 drugs	retatrutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05931367 ↗